A sustainable business model based on innovation and ... - Roche

More documents

Recommendations

Info

Each cancer type is different And needs a specific treatment approach Incidence 100% 80% 60% 40% 3rd line 2nd line 1st line adjuvant 20% Survival 0% CRC BC NSCLC Adjuvant DFS at 3 years* 72 % 81 % 50 % Metastatic median OS * 25 months 36 months 11 months * Assuming best current care, Incidence: GLOBOCAN 2002 and Roche market research 20
First in class mechanisms establishing new standards of care Rank Drug Sales ($m) MAT 3Q08 1 MabThera 4,189 2 Herceptin 4,129 3 Avastin 4,052 4 Glivec 3,491 5 Taxotere 2745 6 Eloxatine 2,236 First in class 7 Arimidex 1,944 8 Gemzar 1,601 9 Erbitux 1,412 10 Casodex 1,343 Successful products need to be first class entrants – the race begins early in R&D 21
Page 1 and 2: Roche A sustainable</strong
Page 3 and 4: Performance up-date Strategy Main t
Page 5 and 6: Performance up-date Our Strategy an
Page 7 and 8: Focus on our core business<
Page 9 and 10: Not to invest in the future means b
Page 11 and 12: Responsible management of R&D spend
Page 13 and 14: Main trends influencing the long-te
Page 15 and 16: Scenarios for PHC Added Value Distr
Page 17 and 18: Key drivers for long term developme
Page 19: Major growth opportunities outside
Page 23 and 24: Avastin: significant potential for
Page 25 and 26: ASCO 2009 Highlights Avastin NSABP
Page 27 and 28: Rheumatoid Arthritis: Not all patie
Page 29 and 30: Performance up-date Strategy Main t
Page 31 and 32: Profitability measures Operating ca
Page 33 and 34: Patent expiry 2008-2012 Roche short
Page 35 and 36: We Innovate Healthcare 35
Page 37: Top 10 Oncology Products Sales and

A sustainable business model based on innovation and ... - Roche

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?